Aprea Therapeutics, Inc. (APRE) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US03836J2015

Price
0.44 USD
Market cap
6.24 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Aprea Therapeutics, Inc. financials

Fiscal year2025
Operating income-13.23 m USD
EBIT-12.60 m USD
Net income-12.60 m USD
Diluted EPS – continuing operations-1.93 USD

Full history since 2007, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.